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ABSTRACT 
A novel series of 1,3,5-trisubstituted-2-pyrazoline derivatives (PFC-1 to PFC-16) were synthesized in a three step 
reaction using conventional and microwave assisted green chemistry approach. The synthesized derivatives were 
characterized and their chemical structures were established by various physicochemical methods such as IR, 
Mass, 1H-NMR, 13C-NMR and elemental analysis. The synthesized compounds were tested for their neurophar-
macological potential. The compounds exhibited significant antidepressant and anti-anxiety activities against var-
ious behavioral in vivo models. Compounds PFC-3 and PFC-12 were found to be the most active derivatives in 
the series. The 2-pyrazoline analogs, having 2-hydroxyphenyl and anthracen-9-yl substitution at 3rd position while 
4-benzyloxyphenyl and 4-methylphenyl substitution at 5th position, were decisive in eliciting good antidepressant 
and anxiolytic properties, respectively. The docking experiments revealed that the synthesized derivatives were 
potential inhibitors of MAO-A protein, which plays a central role in managing depression and anxiety disorders. 
The most potent derivatives were found to be involved in some key interactions with Tyr407, Tyr444, Phe352 and 
Ala68 amino acid residues at the binding site of MAO-A protein. All the synthesized derivatives successfully 
passed the pharmacokinetic barriers of absorption, distribution, metabolism and elimination as predicted using in 
silico techniques without showing any substantial indication of acute and neurotoxicity. This was further con-
firmed in the laboratory by performing acute toxicity studies as per OECD guidelines. 
 
Keywords: 4,5-Dihydro-(1H)-pyrazoles, antidepressant, anxiolytic, MAO inhibitors, neurotoxicity, microwave 
synthesis, molecular docking 
 
 
INTRODUCTION 
The monoamine oxidase (EC 1.4.3.2; 
amine oxygen oxidoreductase) is a FAD-de-
pendent major neurotransmitter degrading en-
zyme present in the outer mitochondria of 
neuronal, glial and other cells, that catalyse 
the aerobic oxidation of structurally diverse 
xenobiotic arylalkylamine substrates includ-
ing neurotransmitters and exogenous amines 
to the corresponding aldehyde and imines 
with the generation of hydrogen peroxide 
(Rose et al., 1989). In mammals MAO exists 
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in two isoforms, MAO-A and MAO-B. Sero-
tonin and norepinephrine are preferentially 
deaminated by MAO-A, which is selectively 
inhibited by clorgyline. However, MAO-B 
deaminates phenylethylamine and benzyla-
mine and is selectively inhibited by l-
deprenil. The proper functioning of synaptic 
neurotransmission is due to rapid degradation 
of biogenic amines, which are critically im-
portant for the regulation of emotional behav-
iors and other brain functions (Manna et al., 
2002). The undesirable elevation in plasma 
concentration of MAO substrates and delete-
rious reactivities shown by MAO-catalyzed 
reaction products are of major concern in 
mental health problems. 
The early development of MAO inhibitors 
started with heterocyclic chemotypes contain-
ing two or more hydrogen atoms, mostly hy-
drazine/hydrazido derivatives (Binda et al., 
2002). However, they have been withdrawn 
due to serious side effects such as hyperten-
sion crises (cheese reaction), liver toxicity, 
hemorrhage, blurred vision, dizziness and in 
some cases death (De Colibus et al., 2005). 
Pyrazolines are considered as cyclic hydra-
zine moieties having two adjacent nitrogen at-
oms within the ring in an envelope confor-
mation. Substituted pyrazolines decorated 
with different functional groups can be con-
sidered as cyclic benzylhydrazine moieties, 
endowed with MAO inhibitory activity (Ed-
mondson et al., 2004). The stability of pyra-
zoline ring system and possible substitutions 
at 1st, 3rd and 5th positions by different aro-
matic and heteroaromatic units inspired the 
researchers to carry out structural modifica-
tions with an array of pharmacological activi-
ties such as antimicrobial, anti-mycobacterial, 
antifungal, anti-amoebic, anti-malarial, anti-
inflammatory, anti-depressant, antiepileptic, 
anticancer, anti-HIV, antitubercular, antibac-
terial, photoluminescence, polarity probes, in-
secticidal, antinociceptive, antioxidant, hypo-
tensive, cholesterol inhibitory, cannabinoid 
(CB1) receptor antagonist, nitric oxide syn-
thase (NOS) inhibitor and MAO inhibitor 
(Abid and Azam 2005; Abid et al., 2009; 
Camacho et al., 2004; Havrylyuk et al., 2009; 
Lange et al., 2005; Patil and Bari, 2014; Pra-
sad et al., 2005; Rathish et al., 2009; Shahar-
yar et al., 2006; Yar et al., 2009; Zampieri et 
al., 2008; Zhang et al., 2007; Chimenti et al, 
2004; Gokhan-Kelekci et al., 2007). 
In order to understand the structural re-
quirements, for both inhibition and selectivity 
towards the two MAO isoforms (MAO-A/ 
MAO-B), it was decided to synthesize some 
novel 1, 3,5 trisubstituted-2-pyrazoline deriv-
atives. The influence on the biological behav-
ior, due to the substitutions of different aro-
matic/heteroaromatic rings at 1st, 3rd and 5th 
position of the pyrazoline nucleus, was in par-
ticular the focus of the study and was further 
corroborated by the computational studies. In 
addition to the conventional heating methods, 
microwave assisted organic synthesis ap-
proach was employed to prepare the proposed 
derivatives. A technique which can be used to 
rapidly explore “chemical space” and in-
crease the vast interaction of the compounds 
produced is known as microwave assisted or-
ganic synthesis. Finally, to predict the binding 
affinity and ascertain the interactions of the 
proposed derivatives with the biological tar-
get, molecular docking studies were per-
formed. 
 
MATERIALS AND METHODS 
The chemicals and reagents for synthesis 
were procured from S. D. Fine Chemicals and 
Sigma Aldrich, Mumbai, India and the pre-
coated TLC sheets were obtained from Merck 
Chemicals, India and were used as such. Rea-
gent grade solvents were used and were puri-
fied and dried by standard methods. Raga's 
Scientific Microwave System (Ragatech, 
Pune, Maharashtra, India) was used for the 
microwave assisted organic synthesis 
(MAOS). Melting points were determined by 
open capillary method and are uncorrected. 
IR spectra were recorded on Bruker FT-IR, 
ALPHA-T (Eco-ATR) spectrophotometers, 
(Bruker Corporation, USA) and the values are 
expressed in cm-1. 1H-NMR and 13C-NMR 
spectra were recorded on Bruker Avance-400, 
FTNMR spectrometer (Bruker, Tech. Pvt. 
Ltd., USA) at 400 MHz and the chemical 
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shifts are reported in parts per million (δ 
value), taking TMS (δ 0 ppm for 1H NMR) as 
the internal standard. Mass spectra were rec-
orded on Waters UPLC-TQD Mass Spec-
trometer instrument (Waters Corporation, 
USA) using LC-ESI or APCI-MS Technique. 
Elemental analysis was performed on Perkin 
Elmer-2400, Series-II Analyzer (Waltham, 
Massachusetts, USA). 
 
Chemistry 
Synthesis of the proposed 2-pyrazoline 
analogs was carried out in three steps using 
conventional methods (stirring and refluxing) 
as well as an environmentally benign green 
synthetic approach under the exposure of mi-
crowave irradiations. It has been observed 
that the entire reactions performed using mi-
crowave assisted organic synthesis (MAOS) 
produced compounds in better yields and at a 
faster rate. 
General procedure for the synthesis of  
chalcones (PC1-PC16) 
Conventional synthesis: Ethanolic KOH 
(60 %, 10 mL) solution was added with stir-
ring over a period of 15 min-2 hrs to the solu-
tion of substituted ketones (0.01 M) and alde-
hydes (0.01 M). The stirring was continued 
for 24-48 hrs at a low temperature (0-10 °C). 
On completion of the reaction, the reaction 
mixture was poured into ice-cold water, and 
then neutralized to pH 2 with hydrochloric 
acid (6N). The yellow colored products ob-
tained were filtered, washed, and re-crystal-
lized from methanol (Jayaprakash et al., 2008; 
Tripathi et al., 2016). 
MAOS: Substituted ketones (0.01 M) and 
aldehydes (0.01 M) were reacted, in presence 
of hydro-alcoholic solution of KOH (60 %, 
10 mL), under microwave irradiation (MWI: 
120-280 W, 60-230 s). On completion of the 
reaction, the reaction mixture was poured into 
ice-cold water, and then neutralized to pH 2 
with hydrochloric acid (6N). The yellow col-
ored products obtained were filtered, washed, 
and re-crystallized from methanol (Jayashree 
et al., 2008; Tripathi et al., 2016). 
General procedure for the synthesis of 3,5-
disubstituted-2-pyrazoline derivatives 
(PS1-PS16) 
Conventional synthesis: The obtained 
chalcone derivatives were refluxed for 3-6 hrs 
with excess of hydrazine hydrate in dry etha-
nol. The hot reaction mixture was poured in 
ice-cold water to obtain the crude product, 
which was washed and re-crystallized from 
appropriate solvent (ethanol/acetone/ethyl ac-
etate) to afford the respective pyrazoline de-
rivative (Karuppasamy et al., 2010; Tripathi 
et al., 2016). 
MAOS: The chalcone derivatives obtained 
were mixed with hydrazine hydrate (in ex-
cess) in dry ethanol under the exposure of mi-
crowave irradiation (MWI: 240-350 W; 50-
400 s). The reaction mixture was poured in 
ice-cold water to get the crude product, which 
was washed and re-crystallized from appro-
priate solvent (ethanol/acetone/ethyl acetate) 
to give the respective pyrazoline derivative 
(Chawla et al., 2010; Insuasty et al., 2011; 
Tripathi et al., 2016). 
General procedure for the synthesis of 1,3,5-
trisubstituted-2-pyrazoline derivatives 
(PFC1-PFC16) 
Conventional method: 3,5-Disubstituted-
2-pyrazolines (0.001M) were reacted with 
0.002 M of 4-chlorobenzenesulfonylchloride 
by stirring, taking tetra hydro furan (10 mL) 
as the solvent. Stirring was continued for 1-
4 hrs. After completion of reaction, the reac-
tion mixture was poured on a petri plate and 
solvent was evaporated to dryness. The sticky 
crude product was re-precipitated using ace-
tonitrile or methanol. Recrystallization was 
done with acetonitrile or methanol to obtain 
the pure product.  
MAOS: Appropriately substituted 3,5-di-
substituted-2-pyrazolines (0.001 M) were re-
acted with 0.002 M of 4-chlorobenzenesul-
fonylchloride under of microwave irradiation 
(MWI: 210-350 W; 80-280 s), taking tetra hy-
dro furan (10 mL) as the solvent. After com-
pletion of reaction, the reaction mixture was 
poured on a petri plate and solvent was evap-
orated to dryness. The sticky crude product 
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was re-precipitated using acetonitrile or meth-
anol. Recrystallization was done with acetoni-
trile or methanol to obtain the pure product. 
Characterization of the synthesized 1,3,5-tri-
substituted-2-pyrazoline derivatives 
Characterization of the intermediate com-
pounds was done with the help of TLC, melt-
ing point and mass spectrometry. However, 
complete physicochemical (Table 1) and 
spectral characterization was carried out for 
the final derivatives and the values were in ac-
cordance with the proposed derivatives. 
2-[1-(4-Chloro-benzenesulfonyl)-5-(4-hy-
droxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-
phenol (PFC-1).  
IR (cm-1): N-H str (3531), C-H Ar (3036), 
C=N str (1596), C-H deform (1491), 
S=O(1349,1162). 1H NMR (DMSO, δ ppm): 
2.00-2.06 (dd, Jab: 15.63 Hz, Jax: 3.47 Hz, 1H, 
Ha), 2.54-2.58 (dd, Jab: 3.78 Hz, Jbx: 16.24 Hz, 
1H, Hb), 3.70-3.73 (dd, Jax: 3.51 Hz, Jbx: 16.14 
Hz, 1H, Hx), 5.23-5.27 (s, 2H, Ar-OH), 6.50-
7.96 (m, 12H, Ar). 13C NMR (DMSO, ppm): 
39.2 (CH2 pyrazoline), 45.1 (CH pyrazoline), 
113.8-146.3 (12CH benzene), 149.6-157.2 
(6C benzene), 161.5 (C pyrazoline). MS 
(m/z): 429 (M+, 100 %). Anal.Calcd. for 
C21H17ClN2O4S: C, 59.66; H, 4.32; N, 6.32. 
Found: C, 59.64; H, 4.36; N, 6.29. 
2-[1-(4-Chloro-benzenesulfonyl)-5-(4-meth-
oxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-
phenol (PFC-2) 
IR (cm-1): N-H str (3361), C-H Ar (3049), 
C=N str (1602), C-H deform (1460), S=O 
(1349, 1165). 1H NMR (DMSO, δ ppm): 
2.30-2.48 (dd, Jab: 17.04 Hz, Jax: 3.06 Hz, 1H, 
Ha), 3.51-3.70 (dd, Jab: 2.87 Hz, Jbx: 15.24 Hz, 
1H, Hb), 3.22-3.50 (dd, Jax: 9.14 Hz, Jbx: 15.11 
Hz, 1H, Hx), 7.23-7.86 (m, 12H, Ar), 8.62 (s, 
1H, OH). 13C NMR (DMSO, ppm): 40.8 (CH2 
pyrazoline), 47.2 (CH pyrazoline), 76.5 (CH2, 
methylene), 113.4-117.1 (4CH aromatic), 
119.1 (2C benzene), 126.8-131.7 (8CH 
aromatic), 135.2 (C benzene), 144.7 (C 
benzene), 158.5 (C pyrazoline), 160.4-160.8 
(2C benzene). MS (m/z): 443.2 (M+, 75 %). 
Anal.Calcd. for C22H19ClN2O4S: C, 59.66; H, 
4.32; N, 6.32. Found: C, 59.70; H, 4.31; N, 
6.35. 
2-[5-(4-Benzyloxy-phenyl)-1-(4-chloro-ben-
zenesulfonyl)-4,5-dihydro-1H-pyrazol-3-yl]-
phenol(PFC-3) 
IR (cm-1): N-H str (3258), C-H Ar (3115), 
C=N str (1605), C-H deform (1448), S=O 
(1380, 1162). 1H NMR (DMSO, δ ppm): 
2.27-2.51 (dd, Jab: 16.74 Hz, Jax: 2.99 Hz, 1H, 
Ha), 3.67-3.94 (dd, Jab: 3.02 Hz, Jbx: 14.23 Hz, 
1H, Hb), 3.15-3.63 (dd, Jax: 9.86 Hz, Jbx: 15.66 
Hz, 1H, Hx), 7.11-7.82 (m, 12H, Ar), 8.62 (s, 
1H, OH). 13C NMR (DMSO, ppm): 41.5 (CH2 
pyrazoline), 49.6 (CH pyrazoline), 79.2 (CH2, 
methylene), 112.7-119.8 (4CH aromatic), 
118.4 (C benzene), 127.3-130.7 (8CH 
aromatic), 135.2 (C benzene), 141.6 (C 
benzene), 157.3 (C pyrazoline), 159.4-160.0 
(2C benzene). MS (m/z): 519.6 (M+, 80 %). 
Anal. Calcd. for C28H23ClN2O4S: C, 64.80; H, 
4.47; N, 5.40. Found: C, 64.83; H, 4.45; N, 
5.41. 
2-[1-(4-Chloro-benzenesulfonyl)-5-p-tolyl-
4,5-dihydro-1H-pyrazol-3-yl]-phenol (PFC-
4) 
IR (cm-1): N-H str (3456), C-H Ar (3083), 
C=N str (1582), C-H deform (1414), S=O 
(1365, 1168). 1H NMR (DMSO, δ ppm): 
2.58-2.71 (dd, Jab: 17.55 Hz, Jax: 3.27 Hz, 1H, 
Ha), 3.70-3.96 (dd, Jab: 3.12 Hz, Jbx: 16.23 Hz, 
1H, Hb), 3.11-3.56 (dd, Jax: 11.47 Hz, Jbx: 
16.22 Hz, 1H, Hx), 4.09 (s, 3H, CH3), 7.14-
7.91 (m, 12H, Ar), 9.02 (s, 1H, OH). 13C 
NMR (DMSO, ppm): 26.5 (CH3, methyl), 
41.7 (CH2 pyrazoline), 48.6 (CH pyrazoline), 
112.7-128.7 (12CH aromatic), 134.2-137.6 
(3C benzene), 157.3 (C pyrazoline), 160.1-
161.9 (2C benzene). MS (m/z): 428.1 (M+1, 
80 %). Anal. Calcd. for C22H19ClN2O3S: C, 
61.89; H, 4.49; N, 6.56. Found: C, 61.91; H, 
4.53; N, 6.57. 
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Table 1: Comparative study of physicochemical properties of synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives (PFC-1 to PFC-16) using conventional and 
microwave methods 
Comps. 
 
Structure 
 
Molecular  
Formula  
Color and 
State 
 
Solubility 
 
Rf 
Value 
Melting 
Range 
(0C) 
Conventional  
Synthesis (Refluxing) 
Microwave Assisted  
Synthesis 
Reaction 
Time (h) 
% Yield Microwave 
Power (W) 
Reaction 
Time (s) 
% 
Yield 
PFC-1 
 
N N
OH
OH
S
O
O
Cl  
C21H17ClN2O4S 
 
Grey col-
ored amor-
phous solid 
DMSO, 
Methanol 
0.84 218-220 3.0 75 240-280 185 86 
PFC-2 
 
N N
OCH3
OH
S
O
O
Cl 
C22H19ClN2O4S 
 
Cream col-
ored amor-
phous solid 
Acetonitrile, 
acetone, 
DMSO, 
methanol 
0.90 196-198 3.0 50 210 90 93 
PFC-3 
 
N N
O
OH
SO
O
Cl  
C28H23ClN2O4S 
 
Light yel-
low colored 
amorphous 
solid 
Acetonitrile, 
acetone, 
DMSO, 
methanol 
0.55 208-210 3.0 62 210-280 110 91 
PFC-4 
 
N N
CH3
OH
S
O
O
Cl 
C22H19ClN2O3S 
 
Light yel-
low colored 
crystalline 
solid 
Acetonitrile, 
chloroform, 
DMSO 
0.82 170-172 2.0 20 240-350 230 82 
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PFC-5 
 
N N
OH
O
H3C S
O
O
Cl 
C22H19ClN2O4S 
 
Yellowish 
grey col-
ored crys-
talline solid 
Methanol, 
acetone, 
DMSO 
0.96 102-104 2.5 50 240-280 170 78 
PFC-9 
 
N N
O
S OO
Cl  
C36H27ClN2O3S 
 
Light yel-
low colored 
amorphous 
solid 
Chloroform, 
acetone, 
DMSO, 
methanol 
0.48 190-192 1.5 75 280-350 120 89 
PFC-10 
 
N N
OCH3
S OO
Cl  
C30H23ClN2O3S 
 
Yellow col-
ored amor-
phous solid 
Chloroform, 
acetone, 
DMSO, 
methanol 
0.90 200-202 0.5 96 280-350 190 85 
PFC-11 
 
N N
OH
S OO
Cl  
C29H21ClN2O3S 
 
Light brown 
colored 
amorphous 
solid 
Chloroform, 
acetone, 
DMSO 
0.56 208-210 2.0 83 280-350 200 85 
PFC-12 
 
N N
CH3
S
O
O
Cl  
C30H23ClN2O2S 
 
Dark brown 
colored 
amorphous 
solid 
Chloroform, 
acetone, 
DMSO, ace-
tonitrile 
0.49 176-178 1.5 36 280 120 60 
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PFC-13 
 N N
N
H O
S OO
Cl  
C26H22ClN3O3S 
 
Black col-
ored amor-
phous solid 
Acetonitrile, 
acetone, 
DMSO, 
methanol 
0.73 118-120 2.0 90 240-350 140 87 
PFC-14 
 
N N
OCH3
N
H
S OO
Cl  
C20H18ClN3O3S 
 
Brownish 
black col-
ored amor-
phous solid 
Acetonitrile, 
acetone, 
DMSO, 
methanol 
0.67 162-64 3.0 54 280-350 280 93 
PFC-15 
 
N N
OH
N
 H S
O
O
Cl  
C19H16ClN3O3S 
 
Black col-
ored amor-
phous solid 
Methanol, 
acetone, ac-
etonitrile, 
DMSO 
0.88 100-102 3.0 40 280 160 81 
PFC-16 
 
N N
CH3
N
 H S
O
O
Cl  
C20H18ClN3O2S 
 
Grey col-
ored amor-
phous solid 
Methanol, 
acetone, ac-
etonitrile, 
DMSO 
0.83 158-160 4.0 75 210-350 175 88 
 
*Rf Values were calculated taking solvent system, Chloroform (9) : Methanol (1) . 
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4-[2-(4-Chloro-benzenesulfonyl)-5-(4-meth-
oxy-phenyl)-3,4-dihydro-2H-pyrazol-3-yl]-
phenol (PFC-5) 
IR (KBr, cm-1): N-H str (3459), C-H Ar 
(2994), C=N str (1598), C-H deform (1451), 
S=O (1340, 1213). 1H NMR (DMSO, δ ppm): 
2.20-2.48 (dd, Jab: 17.04 Hz, Jax: 3.29 Hz, 1H, 
Ha), 3.56-3.85 (dd, Jab: 3.17 Hz, Jbx: 15.23 Hz, 
1H, Hb), 3.15-3.63 (dd, Jax: 9.86 Hz, Jbx: 15.66 
Hz, 1H, Hx), 4.12 (s, 3H, CH3), 7.21-7.79 (m, 
12H, Ar), 8.70 (s, 1H, OH). 13C NMR 
(DMSO, ppm): 41.5 (CH2 pyrazoline), 49.6 
(CH pyrazoline), 60.3 (CH2, methylene), 
115.5-127.3 (12CH aromatic), 128.2-136.4 
(3C benzene), 158.6 (C pyrazoline), 159.4-
160.0 (2C benzene). MS (m/z): 443.7 (M+1, 
80 %). Anal. Calcd. for C22H19ClN2O4S: C, 
59.66; H, 4.32; N, 6.32. Found: C, 59.70; H, 
4.30; N, 6.33. 
3-Anthracen-9-yl-5-(4-benzyloxy-phenyl)-1-
(4-chloro-benzenesulfonyl)-4,5-dihydro-1H-
pyrazole (PFC-9) 
IR (cm-1): N-H str (3301), C-H Ar (3051), 
C=N str (1608), C-H deform (1452), 
S=O(1375, 1178). 1H NMR (DMSO, δ ppm): 
2.60-2.72 (dd, Jab: 15.98 Hz, Jax: 3.33 Hz, 1H, 
Ha), 3.69-3.87 (dd, Jab: 3.16 Hz, Jbx: 15.77 Hz, 
1H, Hb), 3.24-3.58 (dd, Jax: 9.15 Hz, Jbx: 16.86 
Hz, 1H, Hx), 5.11 (s, 2H, CH2), 7.43-7.96 (m, 
22H, Ar). 13C NMR (DMSO, ppm): 41.8 
(CH2 pyrazoline), 49.6 (CH pyrazoline), 78.3 
(CH2, methylene), 128.7-134.4 (21CH 
aromatic), 138.4 (5C aromatic), 160.3 (C 
pyrazoline), 161.4 (C aromatic). MS 
(m/z):603.1 (M+1, 90 %). Anal. Calcd. For 
C36H27ClN2O3S: C, 71.69; H, 4.51; N, 4.64. 
Found: 71.71; H, 4.47; N, 4.65. 
3-Anthracen-9-yl-1-(4-chloro-benzenesul-
fonyl)-5-(4-methoxy-phenyl)-4,5-dihydro-
1H-pyrazole(PFC-10) 
IR (cm-1): N-H str (3379), C-H Ar (3105), 
C=N str (1611), C-H deform (1446), S=O 
(1359, 1178). 1H NMR (DMSO, δ ppm): 
3.02-3.11 (dd, Jab: 17.58 Hz, Jax: 3.13 Hz, 1H, 
Ha), 3.67-3.91 (dd, Jab: 3.29 Hz, Jbx: 15.44 Hz, 
1H, Hb), 327.1-3.56 (dd, Jax: 11.45 Hz, Jbx: 
16.31 Hz, 1H, Hx), 3.73 (s, 2H, CH3), 7.11-
7.82 (m, 17H, Ar). 13C NMR (DMSO, ppm): 
42.6 (CH2 pyrazoline), 47.3 (CH pyrazoline), 
57.2 (CH3 methyl), 125.7-134.3 (17CH 
aromatic), 138.4 (7C aromatic), 157.6 (C 
pyrazoline), 160.0 (C aromatic). MS (m/z): 
528.5 (M+1, 85 %). Anal. Calcd. for 
C30H23ClN2O3S: C, 68.37; H, 4.40; N, 5.32. 
Found: 68.36; H, 4.43; N, 5.28. 
4-[5-Anthracen-9-yl-2-(4-chloro-benzenesul-
fonyl)-3,4-dihydro-2H-pyrazol-3-yl]-phenol 
(PFC-11) 
IR (cm-1): N-H str (3340), C-H Ar (3050), 
C=N str (1575), C-H deform (1421), S=O 
(1380, 1160). 1H NMR (DMSO, δ ppm): 
2.20-2.35 (dd, Jab: 16.45 Hz, Jax: 3.09 Hz, 1H, 
Ha), 3.61-3.90 (dd, Jab: 3.02 Hz, Jbx: 16.23 Hz, 
1H, Hb), 3.15-3.64 (dd, Jax: 11.06 Hz, Jbx: 
15.70 Hz, 1H, Hx), 7.23-7.91 (m, 16H, Ar), 
8.55 (s, 1H, OH). 13C NMR (DMSO, ppm): 
39.8 (CH2 pyrazoline), 49.5 (CH pyrazoline), 
116.7-127.3 (17CH aromatic), 135.2 (7C 
aromatic), 157.3 (C pyrazoline), 162.1 (C 
aromatic). MS (m/z): 528.5 (M+1, 65 %). 
Anal. Calcd. for C29H21ClN2O3S: C, 67.90; H, 
4.13; N, 5.46. Found: C, 67.92; H, 4.16; N, 
5.47. 
3-Anthracen-9-yl-1-(4-chloro-benzenesul-
fonyl)-5-p-tolyl-4,5-dihydro-1H-pyra-
zole(PFC-12) 
IR (cm-1): N-H str (3273), C-H Ar (2925), 
C=N str (1668), C-H deform (1438), S=O 
(1360, 1162). 1H NMR (CDCl3, δ ppm): 2.40 
(s, 3H,), 3.23-3.61 (dd, Jab: 15.28 Hz, Jax: 4.77 
Hz, 1H, Ha), 5.15-5.22 (dd, Jab: 6.33 Hz, Jbx: 
11.27 Hz, 1H, Hb), 7.25-7.58 (m, 4H, Ar), 
7.77-8.49 (m, 8H, Ar). 13C NMR (CDCl3, 
ppm): 21.4 (CH2 pyrazoline), 50.7 (C 
pyrazoline), 76.8-77.6 (2CH aromatic), 
124.5-134.3 (14CH aromatic), 136.2-138.8 
(6C aromatic), 159.4 (C pyrazoline). MS 
(m/z): 512.3 (M+1, 100 %). Anal. Calcd. for 
C30H23ClN2O2S: C, 70.51; H, 4.54; N, 5.48. 
Found: C, 70.50; H, 4.51; N, 5.44. 
5-(4-Benzyloxy-phenyl)-1-(4-chloro-ben-
zenesulfonyl)-3-(1H-pyrrol-2-yl)-4,5-dihy-
dro-1H-pyrazole (PFC-13) 
IR (cm-1): N-H str (3195), C-H Ar (3024), 
C=N str (1602), C-H deform (1444), S=O 
(1356, 1165). 1H NMR (DMSO, δ ppm): 
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2.26-2.52 (dd, Jab: 16.73 Hz, Jax: 2.97 Hz, 1H, 
Ha), 3.66-3.90 (dd, Jab: 3.05 Hz, Jbx: 14.27 Hz, 
1H, Hb), 3.18-3.60 (dd, Jax: 9.76 Hz, Jbx: 15.61 
Hz, 1H, Hx), 5.47 (s, 1H, NH), 6.14 (s, 3H, 
pyrrole), 7.12-7.87 (m, 12H, Ar). 13C NMR 
(DMSO, ppm): 39.8 (CH2 pyrazoline), 52.5 
(CH pyrazoline), 76.2 (CH2, methylene), 
112.7-129.8 (12CH aromatic), 118.4 (3CH 
pyrrole), 127.3-130.7 (8CH aromatic), 137.2-
139.2 (4C aromatic), 157.8 (C pyrazoline), 
159.1 (C aromatic). MS (m/z): 492.3 (M+, 
80 %). Anal. Calcd. for C26H22ClN3O3S: C, 
63.47; H, 4.51; N, 8.54. Found: C, 63.52; H, 
4.49; N, 8.71.  
1-(4-Chloro-benzenesulfonyl)-5-(4-methoxy-
phenyl)-3-(1H-pyrrol-2-yl)-4,5-dihydro-1H-
pyrazole (PFC-14) 
IR (cm-1): N-H str (3382), C-H Ar (3010), 
C=N str (1600), C-H deform (1440), S=O 
(1350, 1121). 1H NMR (DMSO, δ ppm): 
2.18-2.44 (dd, Jab: 16.22 Hz, Jax: 3.07 Hz, 1H, 
Ha), 3.81-3.93 (dd, Jab: 3.12 Hz, Jbx: 15.30 Hz, 
1H, Hb), 3.12-3.66 (dd, Jax: 9.96 Hz, Jbx: 15.21 
Hz, 1H, Hx), 3.51 (s, 3H, CH3), 5.28 (s, 1H, 
NH), 6.39 (s, 3H, pyrrole), 7.17-7.85 (m, 8H, 
Ar). 13C NMR (DMSO, ppm): 39.8 (CH2 
pyrazoline), 52.5 (CH pyrazoline), 59.8 (CH3, 
methyl), 112.7-129.8 (8CH aromatic), 121.1 
(3CH pyrrole), 117.3-126.5 (8CH aromatic), 
137.2-138.6 (3C aromatic), 157.8 (C 
pyrazoline), 160.5 (C aromatic). MS (m/z): 
416.6 (M+, 60 %). Anal. Calcd. for 
C20H18ClN3O3S: C, 57.76; H, 4.36; N, 10.10. 
Found: C, 57.75; H, 4.39; N, 10.08. 
4-[2-(4-Chloro-benzenesulfonyl)-5-(1H-pyr-
rol-2-yl)-3,4-dihydro-2H-pyrazol-3-yl]-phe-
nol (PFC-15) 
IR (cm-1): N-H str (3325), C-H Ar (2997), 
C=N str (1623), C-H deform (1462), S=O 
(1214, 1164). 1H NMR (DMSO, δ ppm): 
2.61-2.84 (dd, Jab: 15.22 Hz, Jax: 3.34 Hz, 1H, 
Ha), 3.63-3.99 (dd, Jab: 2.28 Hz, Jbx: 13.91 Hz, 
1H, Hb), 3.44-3.71 (dd, Jax: 9.58 Hz, Jbx: 14.46 
Hz, 1H, Hx), 5.28 (s, 1H, NH), 6.39 (s, 3H, 
pyrrole), 7.24-7.68 (m, 8H, Ar), 8.23 (s, 1H, 
OH). 13C NMR (DMSO, ppm): 40.3 (CH2 
pyrazoline), 49.8 (CH pyrazoline), 114.1-
128.5 (8CH aromatic), 116.7 (3CH pyrrole), 
135.2-139.6 (3C aromatic), 156.2 (C 
pyrazoline), 162.1 (C aromatic). MS (m/z): 
402.8 (M+, 75 %). Anal. Calcd. for 
C19H16ClN3O3S: C, 56.79; H, 4.01; N, 10.46. 
Found:C, 56.82; H, 3.97; N, 10.41.  
1-(4-Chloro-benzenesulfonyl)-3-(1H-pyrrol-
2-yl)-5-p-tolyl-4,5-dihydro-1H-pyrazole 
(PFC-16) 
IR (cm-1): N-H str (3378), C-H Ar (3182), 
C=N str (1605), C-H deform (1438), S=O 
(1353, 1169). 1H NMR (DMSO, δ ppm): 
2.08-2.34 (dd, Jab: 16.02 Hz, Jax: 3.27 Hz, 1H, 
Ha), 3.61-3.95 (dd, Jab: 3.17 Hz, Jbx: 16.34 Hz, 
1H, Hb), 3.18-3.60 (dd, Jax: 9.81 Hz, Jbx: 15.29 
Hz, 1H, Hx), 2.51 (s, 3H, CH3), 5.33 (s, 1H, 
NH), 6.06 (s, 3H, pyrrole), 7.13-7.69 (m, 8H, 
Ar). 13C NMR (DMSO, ppm): 39.5 (CH2 
pyrazoline), 54.6 (CH pyrazoline), 33.7 (CH3, 
methyl), 118.7-126.8 (8CH aromatic), 118.9 
(3CH pyrrole), 137.2-138.6 (3C aromatic), 
153.8 (C pyrazoline), 155.6 (C aromatic).MS 
(m/z): 401.3 (M+1, 90 %). Anal. Calcd. for 
C20H18ClN3O2S: C, 60.07; H, 4.54; N, 10.51. 
Found: C, 60.11; H, 4.57; N, 10.49. 
 
Biological evaluation 
Study animals 
Animals (male albino mice of BALB/c 
strain, body weight ranging between 20-
35 mg) were obtained from the animal house 
of Faculty of Pharmacy, BBDNIIT, Lucknow, 
U.P., India and kept in polymeric cages under 
standard living conditions of 26±2 ºC temper-
ature and 55±5 percent humidity, with regular 
light and dark cycles, having free access to 
standard food and water. Animals were 
treated humanely as per the Institutional Ani-
mal Ethics Committee (IAEC) guidelines. 
The pharmacological studies were approved 
by the IAEC with protocol number 
BBDNIIT/IAEC/008/2014.  
Study design 
For the study, animals were divided into 
29 groups, each group consisting of 6 animals 
(n=6). All the mice were treated at respective 
doses according to body weight. Treatments 
including standard/vehicle/test compounds 
were given at 1 mL/100 g body weight per 
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oral (p.o.). Imipramine (10 mg/kg body 
weight) for antidepressant activity, and Diaz-
epam (2 mg/kg body weight) for anti-anxiety 
activity was respectively taken as the standard 
drugs. Carboxy methyl cellulose (0.5 % CMC 
solution) was taken as the vehicle (control 
group). The groups and respective doses are 
given in Table 2. 
Antidepressant activity 
Forced swim test (FST) and Tail suspen-
sion test (TST) in mice model were used to 
screen the antidepressant potential of the pre-
pared compounds (PFC1-PFC16). These be-
havioral in vivo tests have been successfully 
used to screen and predict the efficacy and po-
tency of various antidepressant treatments in-
cluding MAO inhibitors (Porsolt, 1981; Will-
ner and Mitchell, 2002). 
- Porsolt’s behavioral despair or 
forced swim test (FST) in mice 
Antidepressant potential of the synthesiz-
ed compounds was tested using Porsolt’s be-
havioral despair test, i.e. FST. Typical immo-
bility behaviors of mice are induced when 
they are forced to swim in a limited space 
from where they cannot flee. During the test, 
mice were plunged into a glass cylinder con-
taining water and it was observed that the an-
imals, after the first 2 min of the initial strug-
gle, became motionless. The duration of still-
ness was considered when mice started float-
ing in water in a vertical position, with modest 
activities in order to prevent sinking, and was 
documented specially for the last 4 min of the 
6 min test. This behavior is explained as a 
state of despair which can be minimized by 
different therapeutically effective antidepres-
sants, measured by comparing animals treated 
at numerous doses of test or standard drugs 
with control (Porsolt et al., 1977; Vogel, 
2002).  
- Tail suspension test (TST) in mice 
This procedure is simple, uses objective 
test situations and the results are congruent 
with the validated "behavioral despair" test 
from Porsolt showing sensitivity towards var-
ious drug doses. TST is a superficial method 
and was used to evaluate the antidepressant 
potential of test compounds, where the mouse 
is hanged through its tail using a lever. The 
total 6 min test duration was segregated into 
agitation and immobility periods. The rodents 
showed the state of immobility once they 
were exposed to an inescapable stress. In 
TST, the potential antidepressants minimize 
the state of immobility of mice after active 
and unsuccessful attempts to escape, when 
compared with the vehicle treated controls. 
The locomotor stimulant doses of the tested 
compounds can be differentiated from antide-
pressant doses, when the period of serenity is 
studied in conjunction with locomotor activ-
ity(Steru et al., 1985; Vogel, 2002).  
Anti-anxiety activity 
The most frequently used method to study 
anti-anxiety behavior of the test compounds is 
the maze model. Elevated plus maze has 
found a better acceptance in several laborato-
ries in comparison to the other mazes, such 
as-water maze, Y-maze and radial maze. This 
test selectively identifies the anxiolytic (open 
arm exploration time is increased and time 
spent in closed arms is decreased) and anxio-
genic drugs with opposite effects. The values 
are represented in percent of control. Open 
arm exploratory time is increased while motor 
activity is decreased by benzodiazepines and 
valproates (Vogel, 2002). 
- Elevated plus-maze test 
The elevated plus-maze is used to deter-
mine the anxiety-related behavior, measured 
by the extent to which the mouse avoids to 
visit the open arm of the maze. It is a standard 
test of fear and anxiety where animals are po-
sitioned at the middle of an elevated four-arm 
maze, in which two arms were open (50 X 10 
X 40 cm) and 2 arms are closed (50 X 10 X 
40 cm), with an open roof situated on the op-
posite side. The maze was elevated to a height 
of 50 cm. After, one hour of oral administra-
tion of the standard drug (Diazepam at a dose 
of 2 mg/kg b.w.), test compound (at doses; 50 
and 100 mg/kg b.w.) and control (0.5 % aque-
ous CMC suspension), the mice were put in 
the middle of the maze, facing the closed arm. 
The observations were recorded during the 6 
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Table 2: Data showing antidepressant, anti-anxiety and neurotoxicity studies of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (PFC-1 to PFC-16). 
Comps. Group 
Number 
Doses(m
g/kg b.w.) 
Antidepressant Activitya Anti-anxiety Activityb Neurotoxicity Studies 
Rotarod Testc 
 
Actophotometer Testd 
(Mean Counts) 
Duration of 
Immobility in 
FST (sec) 
(Mean±SD) 
Duration of 
Immobility in 
TST (sec) 
(Mean±SD) 
Number of 
Entries in 
Closed Arms 
(Mean±SD) 
Time Spent in 
Closed Arms 
(sec) 
(Mean±SD) 
Before 
Dose 
After Dose 
(After 1 h) 
Before Dose After Dose 
(After 1 h) 
PFC-1 
1  50 105.67 ± 11.69 145.17 ±18.70 5.50±2.26 245.00±22.86 0/6 0/6 283.83 290.50 
2  100 79.83 ± 7.57 178.00±10.64 6.67±2.16 227.00±15.89 0/6 0/6 306.33 307.83 
PFC-2 
3  50 104.33 ± 14.77  196.17±18.65 6.33±2.07 254.83±14.40 0/6 0/6 283.83 287.17 
4  100 86.50 ± 8.24 196.83±12.56 6.50±1.38 223.50±19.94 0/6 0/6 288.83 290.50 
PFC-3 
5  50 55.50 ± 9.18 151.33±29.56 6.33±1.97 270.17±24.38 0/6 0/6 284.17 282.50 
6  100 27.17 ± 5.42 22.17±9.62 6.67±2.16 195.00±50.54 1/6 1/6 306.33 306.33 
PFC-4 
7  50 96.67 ± 16.82 139.33±20.17 6.17±2.14 216.50±29.54 0/6 0/6 283.83 283.83 
8  100 85.50 ± 10.50 125.50±13.75 7.00±1.41 229.00±37.53 0/6 0/6 418.33 423.83 
PFC-5 
9  50 82.67 ± 6.41 209.17±23.61 5.00±2.00 192.33±25.32 0/6 1/6 413.17 411.17 
10  100 74.83 ± 16.82 160.33±13.44 8.50±2.59 215.83±22.02 0/6 0/6 306.33 306.33 
PFC-9 
11  50 55.17 ± 5.71 97.50±30.25 11.00±3.90 142.50±25.00 0/6 0/6 413.17 419.67 
12  100 49.83 ± 9.66 65.50±29.61 14.67±2.34 135.83±14.69 0/6 0/6 306.33 306.33 
PFC-10 
13  50 105.17 ± 13.85 150.50±24.74 6.00±1.41 264.67±26.40 0/6 0/6 283.83 299.50 
14  100 87.83 ± 18.79 155.83±12.80 8.83±2.48 252.67±34.77 0/6 0/6 288.83 288.83 
PFC-11 
15  50 104.17 ± 15.56 89.83±14.94 4.50±1.87 203.00±22.65 0/6 1/6 306.33 302.67 
16  100 99.50 ± 14.64 199.50±15.58 6.33±3.27 153.17±40.90 0/6 0/6 280.83 280.83 
PFC-12 
17  50 129.17 ± 11.23 127.50±27.81 10.83±3.66 169.17±18.50 0/6 0/6 330.67 321.33 
18  100 97.67 ± 14.19 93.17±11.82 16.67±2.58 133.83±12.51 0/6 0/6 286.00 288.00 
PFC-13 
19  50 57.00 ± 8.67 107.17±27.46 7.83±3.19 256.17±20.85 1/6 0/6 296.50 295.17 
20  100 43.33 ± 10.98 100.83±16.19 8.67±2.16 211.50±25.10 0/6 0/6 284.17 285.67 
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PFC-14 
21  50 56.33 ± 10.21 54.67±14.36 6.17±2.14 206.83±16.12 0/6 0/6 418.33 423.83 
22  100 21.17 ± 8.33 36.83±11.29 9.83±2.86 187.33±12.56 0/6 0/6 413.17 413.17 
PFC-15 
 
23  50 110.83 ± 16.65 110.17±14.95 8.67±2.34 216.50±16.84 0/6 0/6 226.67 236.83 
24  100 84.67 ± 13.34 87.67±10.56 12.67±3.27 158.67±20.77 1/6 0/6 306.33 324.33 
PFC-16 
25  50 155.00 ± 11.64 149.17±38.29 2.67±2.73 202.00±11.35 0/6 2/6 291.67 281.33 
26  100 101.67 ± 12.26 132.17±11.32 5.17±2.79 144.00±66.83 0/6 0/6 288.83 284.17 
Control 
(CMC) 27  0.5 % 179.67± 18.67 219.00±17.56 0.83±0.75 281.67±41.09 0/6 0/6 305.50 309.00 
Standard 
drug 
(Imipramine) 
 10 29.33±8.43*** 60.33±9.33*** --- --- 0/6 0/6 316.17 313.17 
Standard 
drug 
( Diazepam) 
28  2 --- --- 9.33±3.08*** 177.33±45.18
*
** 0/6 0/6 286.00 284.17 
Bold data represent the most active compounds in the series. 
n=6 (Number of animals tested at each dose level). 
***p < 0.05. 
Control: Carboxy methyl cellulose (CMC, 0.5 % suspension). 
Standard: Imipramine (10 mg/kg, b.w.) for antidepressant activity and Diazepam (2 mg/kg, b.w.) for anti-anxiety activity. 
a The reduction in time of immobility in FST and TST are established ways to evaluate effectiveness of antidepressants.  
b The number of entries is increased in anxiolytic agents and decreased in anxiogenic agents and the amount of time spent in closed arms is decreased in anxiolytic agents and increased 
in anxiogenic agents.  
c Neurotoxicity was evaluated in rotarod test before dosing and after 1 hour of dosing (number of animals exhibiting toxicity/number of animals tested).  
d Neurotoxicity recorded in actophotometer test (Counts recorded in 10 minutes duration) 
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min test duration: time spent in closed arm 
and total number of the arm entries(Lister, 
1987; Pellow et al., 1985). 
Neurotoxicity study  
Neurotoxicity studies are used to screen 
the effect(s) of a test substance on the CNS. 
Several behavioral studies (such as rotarod 
test, open-field/actophotometer test, turning 
on flat surface and turning on inclined plane) 
are employed to identify potential neurotoxi-
city in mice model. Rotarod and actophotom-
eter tests are the two most often used methods 
to identify the effect of chemical compounds 
(test compound) on neuromuscular coordina-
tion and locomotor activities, respectively 
(Parasuraman, 2011). 
- Neuromuscular coordination study 
(rotarod test) 
The rotarod test is valuable to find out the 
consequences of drug on motor coordination, 
i.e. neurotoxicity. This test was introduced by 
Dunham and Miya in 1956, where relaxation 
of skeletal muscle produced by any test com-
pound is examined by maintaining the ability 
of mice or rats on a rotating rod, at a speed of 
10 revolutions per min. For the test, male 
mice of average weight 25±5g underwent a 
pretest, and only those mice were selected for 
the test which remained on the revolving rod 
for at least 1 minute. The mice were placed on 
the rod after 1 hour of oral administration of 
test compounds/standard drug/control. At this 
speed, normal mice stay on the rod for an in-
definite period of time. However, if they fall 
before 1 min, the sign of neurotoxicity is ap-
parent at the tested doses. Therapeutic end 
point is considered as a dose which persuades 
ability of fifty per cent of the mice to stay on 
the revolving rod. Number of animals falling 
down from the rod is counted in a qualitative 
manner and mean fall off time is recorded to 
quantify the values (Bhandari et al., 2013; 
Vogel, 2002). 
- Locomotor activity (actophotometer/ 
open field test) 
Locomotor activities of animals, and hu-
mans, are affected by majority of the CNS act-
ing drugs and therefore it is utilized as an in-
dex of their mental alertness. Some CNS de-
pressant drugs like barbiturates and alcohols 
have been found to reduce it. However, CNS 
stimulants like amphetamines and caffeine 
exhibit significant increase in the motor activ-
ity. The locomotor activity was examined for 
a 10 minute duration, using Medicraft Acto-
photometer (Model No. 600-4D, INCO, Am-
bala, India), to rule out such CNS depressant 
or stimulant type of effects of the tested com-
pounds. During the test, animal moves in a 
square arena of dimension 30x30x25 cm with 
mesh wire bottom. Photoelectric cells con-
nected in circuit with a counter are used to op-
erate the apparatus, where light beam striking 
on the photo cell is cut off by the animal to 
record a count(Dhingra and Goyal, 2008). 
Acute toxicity study 
Acute toxicity testing is carried out to de-
termine the effect of a single dose on a partic-
ular animal species. In the present study, 
acute oral toxicity (LD50) of two most active 
final derivatives (PFC-3 and PFC-12) was 
performed as per guidelines laid by Organiza-
tion for Economic Co-operation and Develop-
ment (OECD) guideline No 423 “Acute Oral 
Toxicity - Acute Toxic Class Method”. The 
compounds were administered orally at four 
fixed dose levels (5, 50, 300 and 2000 mg/kg 
body weights), after 4 hours of fasting. After 
dose administration, food but not water was 
withheld for 2 hours. The body weight of all 
the mice were recorded on study days D0 (in-
itiation), D1, D7 and D14. The animals were 
observed for 4 hours post dose treatment and 
thereafter for 14 days for mortality, including 
various signs of toxicity such as, changes in 
skin and fur, behavior patterns, convulsions, 
tremors and death(OECD, 2001; Parasura-
man, 2011). 
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Molecular docking studies 
Molecular docking simulations were used 
to predict binding affinity and binding orien-
tations of the synthesized compounds with 
MAO-A protein (PDB ID: 2Z5X), using 
GLIDE program. The X-ray crystal structure 
of MAO protein was retrieved from the Pro-
tein Data Bank (PDB) and optimized using 
“protein preparation wizard”. Ligands were 
prepared by LigPrep module 3.2 version 
v25111(Schrödinger, LLC, New York, NY, 
2014), using OPLS (optimized potential liq-
uid simulations) 2005 force field to give the 
consequent energy minima. Default settings 
were applied to other parameters. Rigid dock-
ing was performed during these calculations. 
Re-docking experiment was conducted to val-
idate the docking procedure, in which the co-
ordinates of crystal ligand were obtained from 
the PDB structure of MAO-A protein-ligand 
complex and docked back into the binding 
pocket. GLIDE (version 6.5, Schrödinger, 
LLC, New York, NY, 2014) program per-
fectly reproduced the tentative pose of the lig-
and and accurately predicted the binding 
mode. 
In silico prediction of pharmacokinetic  
properties 
Majority of the drug candidates do not 
succeed in clinical trials due to poor pharma-
cokinetic properties, such as absorption, dis-
tribution, metabolism, and excretion 
(ADME). The outlay in developing new drug 
significantly increases due to these later-stage 
failures, which can be radically reduced if the 
problematic candidates are detected in early 
phases. In this study, the QikProp module 
(version 4.2) of Schrödinger (LLC, New 
York, NY, 2014) software program was suc-
cessfully employed for in silico prediction of 
ADME properties of the synthesized deriva-
tives. 
In silico toxicity prediction  
There are a large number of freely availa-
ble computer programs to envisage the in sil-
ico toxicity of the compounds. Two of these 
softwares, used in this study are; LAZAR and 
OSIRIS Property explorer. LAZAR provides 
a generic tool for predicting complex toxico-
logical end points, such as carcinogenicity, 
long-term toxicity, and reproductive toxicity. 
Virtual Computational Chemistry Laboratory 
maintains OSIRIS as a fundamental part of 
Actelion's in house substance registration sys-
tem. This calculates various drug-related 
properties of chemical structures including 
some toxicity parameters and drug likeness. 
Predicted outcomes are rated and color coded. 
Properties such as mutagenicity or a poor in-
testinal absorption having higher risks of un-
desired effects are shown in red, whereas a 
green color indicates drug-conform behav-
ior(Klebe, 2000). 
 
Statistical analysis 
All the values of the experimental results 
are expressed as mean±SD and analyzed by 
one-way ANOVA, followed by Dunnett’s test 
for the possible significance (P<0.05) identi-
fication between various groups. Statistical 
analysis was carried out using Graph Pad 
Prism 5.0 (Graph Pad Software, San Diego, 
CA). 
 
RESULTS AND DISCUSSION 
A series of thirteen 2-pyrazoline deriva-
tives (PFC1 to PFC-16) were synthesized us-
ing conventional as well as a green chemistry 
approach of microwave assisted organic syn-
thesis (MAOS) as given in Figure 1. Among 
the two methods, MAOS showed better syn-
thetic efficiency when compared with the 
conventional procedures. The synthesized de-
rivatives were characterized by various phys-
icochemical (Table 1), spectral and elemental 
analysis methods. The spectral analysis data 
expound C=N stretching (1509-1612 cm-1), 
N-H stretching (3456-3105 cm-1) and C-H de-
formation (1428-1357 cm-1) along with a 
characteristic peak of sulfonyl group absorp-
tion bands (1340-1180 cm-1) in the corre-
sponding regions of IR spectra.
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R-CHO + C2H5OH,  KOH
0-10 oC, Stir, 24-48 hrs.
Chalcone derivatives
(PC1-PC16)
Aldehyde Ketone
CH3
O
R' R
H
C
C
H
R'
O
OHWhere R:
OH
and R':
OCH3 O CH3
H2
C
OCH3 N
H
Conventional Method
Microwave Method
MWI: 120-280W, 40-190s
Reflux, 3-6 hrs.
N NH
RR'
3,5-Disubstituted 
2-pyrazoline derivatives
(PS1-PS16)
NH2NH2.H2O
Conventional Method
Microwave Method
MWI: 240-350W, 50-250s
Conventional Method
Microwave Method
Stir, 1-4 hrs.
1,3,5-Trisubstituted 
2-pyrazoline derivatives 
(PFC1-PFC16)MWI: 210-350W, 80-280s
N
N
R
R'
S
O
O
Cl
4-Chlorobenzenesulfonyl chloride
 
 
Figure 1: Synthesis of 1,3,5-Trisubstituted-2-pyrazoline derivatives 
 
 
 
The presence of two non-equivalent pro-
tons of a methylene group (Ha/Hb) at δ 2.92–
3.38 ppm and 3.70–3.93, coupled with each 
other and in turn with the vicinal methine pro-
ton (Hx) at δ 6.68–7.04 were recorded in the 
1H-NMR spectra. All the other protons of var-
ious aliphatic/aromatic/heteroaromatic groups 
were anticipated at respective places. 
Results of the pharmacological studies 
demonstrated that the synthesized 1,3,5-tri-
substituted-2-pyrazoline derivatives possess 
good range of antidepressant and anti-anxiety 
activities, as evaluated using various in vivo 
models. Compounds PFC-3 and PFC-12 
were found to be the most active compounds 
amongst all the synthesized derivatives (Ta-
ble 2 and Figure 2).  
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Figure 2: (a) Graph showing anti-anxiety activity (Number of entries in closed arms in Elevated Plus 
Maze Test); (b) Graph showing anxiety activity (Time spent in closed arms in Elevated Plus Maze Test); 
(c) Graph showing antidepressant activity (Forced Swim Test); (d) Graph showing antidepressant ac-
tivity (Tail Suspension Test).For each group, number of animals tested was 6 (n=6).  
 
 
Detailed SAR studies revealed that 4-
chlorobenzenesulfonyl substitution at N1 po-
sition was decisive in exhibiting good antide-
pressant and anti-anxiety activities. It was 
also observed that 2-hydroxyphenyl substitu-
tion at 3rd position and 4-benzyloxyphenyl 
substitution at 5th position of 2-pyrazoline nu-
cleus was instrumental for the remarkable an-
tidepressant potency of compound PFC-3. 
However, a bulky hydrophobic anthracen-9-
yl substitution at 3rd position and 4-
methylphenyl substitution at 5th position of 
the 2-pyrazoline scaffold were favorable in 
demonstrating the significant anxiolytic pro-
file of compound PFC-12. The biological ac-
tivities of the synthesized compounds were 
depending upon the doses administered, with 
increased effects at higher tested dose 
(100 mg/kg b.w.). 
All the synthesized derivatives were also 
evaluated for their possible neurotoxicologi-
cal effects such as neuromuscular coordina-
tion (using rotarod test) and locomotor activ-
ity (using actophotometer test). It was ob-
served that none of the synthesized com-
pounds showed serious neurotoxicity (dis-
turbances in the motor co-ordinations and lo-
comotor activity) threats at the tested doses 
(Table 2). Therefore, any possibility of CNS 
stimulating or depressing effects of the tested 
compounds was ruled out. Additionally, two 
most potent derivatives (PFC-3 and PFC-12) 
were screened for their acute toxicities, at the 
tested doses. During these studies; behavioral 
pattern, changes in skin and fur, convulsions, 
tremors and death were not observed in any of 
the animals, in due course of 14 days of acute 
toxicity studies, as per the OECD guidelines. 
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The results obtained by animal experi-
mentation were further supported by the out-
comes of molecular docking experiments. 
The antidepressant and anxiolytic properties 
of substituted 2-pyrazoline derivatives may 
be attributed to their MAO-A inhibiting capa-
bilities. The synthesized compounds were 
found to possess tremendous affinity towards 
MAO-A enzyme, and may therefore be 
deemed as imperative targets to develop po-
tential neuropharmacological agents. Dock-
ing studies also confirmed that the presence of 
sulfonyl group at N1 position of pyrazoline 
nucleus establishes a hydrogen bonding inter-
action between the sulfonyl oxygen of the lig-
ands and hydroxyl hydrogen of either Tyr444 
or Tyr407 amino acid residue. Due to these 
Hydrogen bonding interactions, substituted 
phenyl ring at C5 and benzenesulfonyl ring at 
N1 position of pyrazoline nucleus are well 
placed in the aromatic cage. The most potent 
compound from N1 benzenesulfonyl substi-
tuted series (PFC-12) displayed additional 
key interactions of this moiety with side chain 
and backbone residues of the amino acids at 
the binding pocket. This included a hydropho-
bic interaction of benzene ring with Tyr 407, 
Tyr444 residues, and H-bond interaction with 
Ala68 and Tyr444 residues (Figure 3 and 4). 
 
 
Figure 3: Ligand receptor interaction diagram of compound PFC-3 at the binding site of MAO-A protein 
(PDB ID: 2Z5X) showing best anti-anxiety activity. (a) 2D Ligand receptor interaction diagram, (b) 3D 
Ligand receptor interaction diagram 
 
 
Figure 4: Ligand receptor interaction diagram of compound PFC-12 at the binding site of MAO-A protein 
(PDB ID: 2Z5X) showing best antidepressant activity. (a) 2D Ligand receptor interaction diagram, (b) 
3D Ligand receptor interaction diagram 
EXCLI Journal 2017;16:628-649 – ISSN 1611-2156 
Received: March 04, 2017, accepted: April 28, 2017, published: May 08, 2017 
 
 
645 
It was observed that one amongst the other 
aromatic substitutions of previously men-
tioned compounds at these positions is in-
volved in hydrophobic and probably aromatic 
interaction. Also, favorable in silico ADME 
performances (Table 3) were obtained for all 
the synthesized compounds. Furthermore, the 
tested compounds were found to be safe, by 
not presenting any potential risks of carcino-
genicity, mutagenicity, reproductive toxicity, 
acute toxicity and irritancy as predicted by 
LAZAR and OSIRIS Property Explorer pro-
grams (Table 4). 
 
CONCLUSION 
In the present study, in vivo and in silico 
screening results have clearly demonstrated 
the expediency of synthesized 2-pyrazoline 
derivatives in neuropharmacological disor-
ders. Although, the evidence showed promis-
ing status of the tested compounds against in 
vivo models of depression and anxiety, further 
experiments including in vitro MAO-A inhi-
bition studies are needed to explore their con-
crete mechanism of action at molecular level. 
Since, all these derivatives were found to be 
effective in a dose dependent manner, further 
therapeutic dose adjustment studies and de-
signing of most appropriate dosage forms are 
some imperative prospects. Some of the ex-
cellent outcomes obtained from the preclini-
cal investigations demand comprehensive 
clinical trials to establish the role of synthe-
sized 1,3,5-trisubstituted-2-pyrazoline deriv-
atives in the management of depression and 
anxiety disorders.  
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Table 3: In silico prediction of binding affinity (Glide gscore) and ADME parameters of the synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives (PFC-1 to 
PFC-16) 
#stars: Number of property or descriptor values that fall outside the 95 % range of similar values for known drugs 
Volume: Total solvent accessible volume in cubic angstrom using a probe with 1.4 Ǻ radius 
PSA: Van der Waals polar surface area of nitrogen and oxygen atoms 
SASA: Total solvent accessible surface area in square angstrom using a probe with 1.4 Ǻ radius 
donarHB: Hydrogen bond donar 
accptHB: Hydrogen bond acceptor 
CNS: Predicted central nervous system activity at -2 (inactive) to +2 (active) scale 
QPlogBB: Predicted brain/blood partition coefficient 
QlogPo/w: Predicted octanol-water partition coefficient 
QPlogKhsa: Prediction of binding to human serum albumin 
QPPCaco: Predicted apparent Caco-2 cell permeability in nm/sec 
metab: Number of likely metabolic reactions, Number of violations of Lipinski’s rule of five 
  
Comps. Glide 
gscore 
MW Volume PSA Donar
HB 
accpt 
HB 
CNS 
 
Qlog 
Po/w  
QPlog
BB 
QPlog 
Khsa 
metab % Human 
Oral ab-
sorption 
Violations 
of Rule of 
Five 
PFC-1 -9.36 428.89 1156.63 94.96 2 7.00 -2 3.04 -1.025 0.27 4 87.79 0 
PFC-2 -9.10 442.92 1191.49 80.71 1 7.00 0 3.63 -0.646 0.34 4 100 2 
PFC-3 -11.15 519.01 1432.31 79.62 1 7.00 -1 5.29 -0.926 0.88 5 83.04 0 
PFC-4 -8.97 426.92 1190.23 72.43 1 6.25 0 3.95 -0.573 0.53 4 100 0 
PFC-5 -9.76 442.92 1220.09 81.08 1 7.00 -1 3.76 -0.736 0.41 4 100 0 
PFC-9 -8.55 603.13 1698.69 58.48 0 6.25 0 7.84 -0.459 1.67 4 100 2 
PFC-10 -6.74 527.04 1458.19 59.58 0 6.25 0 6.10 -0.228 1.05 3 96.27 2 
PFC-11 -10.09 513.01 1459.47 74.92 1 6.25 0 5.98 -0.695 1.21 3 88.28 2 
PFC-12 -10.20 511.04 1496.30 52.38 0 5.50 0 6.89 -0.174 1.41 3 100 2 
PFC-13 -9.19 491.99 1366.97 74.17 1 6.25 -1 5.31 -0.734 0.90 4 100 1 
PFC-14 -7.82 415.89 1127.11 75.25 1 6.25 0 3.66 -0.461 0.37 3 100 0 
PFC-15 -10.19 401.87 1091.93 89.50 2 6.25 -1 3.05 -0.943 0.28 3 90.99 0 
PFC-16 -8.69 399.89 1125.05 66.96 1 5.50 0 3.96 -0.389 0.55 3 100 0 
Crystal 
Ligand(2Z5X) -6.89 212.25 733.39 33.50 1 1.75 
0 3.11 0.180 0.222 3 100 0 
Standard 
values --- 
130 to 
725 
500 to 
2000 
7 to 
200 0 to 6 2 to 20 
-2 to 
+2 
-2.0 to 
6.5 
-3.0-
1.2 
-1.5 to 
1.5 1 to 8 
<20% poor, 
>80% high Max. is 4 
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Table 4: In silico toxicity prediction data of the synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives(PFC-1 to PFC-16) 
Comp. 
Toxicity prediction 
OSIRIS Property Explorer LAZAR 
Mutagenic Tumorigenic Irritant Reproductive effect Mutagenicity 
Maximum recom-
mended daily dose 
(mmol) 
Acute tox-
icity LC50 
(mmol) 
Carcinogenic 
potency 
 PFC-1 No risk No risk No risk No risk 2.74e+00 Inactive 9.92e+00 Inactive 
 PFC-2 No risk No risk No risk No risk 4.34e+00 Inactive 1.82e+01 Inactive 
 PFC-3 No risk No risk No risk No risk 3.05e+00 Inactive 3.00e+01 Inactive 
 PFC-4 No risk No risk No risk No risk 6.99e+00 Inactive 8.88e+00 Inactive 
 PFC-5 No risk No risk No risk No risk 2.07e+01 Inactive 1.29e+01 Inactive 
 PFC-9 High risk No risk No risk No risk 5.97e+00 Inactive 1.66e+01 Active 
 PFC-10 High risk No risk No risk No risk 5.37e+00 Rat: active Mouse: inactive 9.73e+00 Active 
PFC-11 High risk No risk No risk No risk 2.78e+00 Inactive 1.20e+01 Active 
 PFC-12 No risk No risk No risk No risk 1.12e+01 Inactive 1.17e+01 Inactive 
 PFC-13 Medium risk No risk No risk No risk 1.79e+01 Inactive 1.04e+01 Inactive 
 PFC-14 Medium risk No risk No risk No risk 1.89e+01 Inactive 6.81e+00 Inactive 
 PFC-15 Medium risk No risk No risk No risk 9.03e+00 Inactive 1.84e+01 Inactive 
 PFC-16 Medium risk No risk No risk No risk 1.40e+01 Inactive 1.63e+01 Inactive 
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